Companies are likely to use the Unitary Patent system and believe it will be good for innovation in Europe, according to a survey of in-house patent counsel conducted by Managing IP. But they overwhelmingly want more information on how it will work, with details of costs their biggest priority
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
Novo Nordisk losing patent rights covering Ozempic in Canada and a US Supreme Court decision favouring Ed Sheeran were also among the top talking points
Jorg Thomaier, who has been head of IP at the German pharma company since 2010, will leave later this year and hand the reins to the company’s head of patents